Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep’s Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action

Trial-in-progress abstract highlights new cohort that could expand the company’s pancreatic cancer program   Pelareorep’s ability to expand TILs highlights its immunotherapeutic mechanism of action and potential as a backbone immunotherapy for multiple indications    San Diego, CA and Calgary, AB –  May 24, 2024 – Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading […]

Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer

US$5 million PanCAN grant provides important support for the fifth cohort of the GOBLET study   Study of modified FOLFIRINOX/pelareorep/atezolizumab (Tecentriq ® ) combination expands existing pancreatic cancer program   First patient expected to be enrolled in Q2 2024   San Diego, CA & Calgary, AB – May 9, 2024 – Oncolytics Biotech ® Inc. (NASDAQ: […]

Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA

Requested for Q2 2024, the Type C meeting is to focus on planned registration-enabling trial in HR+/HER2- metastatic breast cancer Overall survival results from the randomized HR+/HER2- metastatic breast cancer BRACELET-1 trial expected in H2 2024   San Diego, CA and Calgary, AB  – April 11, 2024 – Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: […]

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market – A Race Worth

Vancouver, Kelowna and Delta, British Columbia – March 6, 2024 – Investorideas.com, a global investor news source covering biotech and pharma stocks issues a sector snapshot on developments for pancreatic cancer treatments, featuring Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology.   Read the full article on Investorideas.com   […]

Cancer Immunotherapy Stocks – Tapping into Immune Systems for Next Generation Treatments

Vancouver, Kelowna and Delta, British Columbia – February 15, 2024) – Investorideas.com, a global investor news source covering biotech and pharma stocks issues a sector snapshot on cancer immunotherapy featuring Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology.   Read the full article at Investorideas.com https://www.investorideas.com/news/2024/biotech/02150Cancer-Immunotherapy.asp   According to […]

Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort

Successful Stage 1 data showed a near tripling of Objective Response Rate compared to checkpoint inhibitor monotherapy, including a Complete Response, and supports expansion   San Diego, CA and Calgary, AB –  February 14, 2024 — Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the expansion of […]

Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directors

SAN DIEGO, CA and CALGARY, AB – January 9, 2024 – Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the appointment of Patricia S. Andrews to its Board of Directors (the “Board”).   “I am pleased to welcome Pat Andrews to our Board of Directors,” said Dr. […]

Oncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024

San Diego, CA and Calgary, AB – January 4, 2024 – Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, reported on significant 2023 accomplishments and announced corporate priorities and anticipated clinical development milestones for 2024.   Overview : “2023 was an outstanding year for Oncolytics and the development […]

Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy

Pelareorep-atezolizumab combination data exceeds historical control trials with a 37.5% objective response rate, including a complete response   San Diego, CA, and Calgary, AB – November 9, 2023 – Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) (Oncolytics), a clinical-stage immunotherapeutics company focused on oncology, today announced the presentation of positive, interim results from the Phase […]